374822-45-4

Upstream product

• 374822-44-3 2-({2-[3,5-bis(trifluoromethyl)phenyl]ethyl}thio)benzothiazole 
• 120-78-5 di(benzothiazol-2-yl)disulfide 
• 93427-28-2 3,5-Bis(trifluoromethyl)-β-phenethyl alcohol 

Downstream Products

• 374901-76-5 cis- and trans-(E)-4-(4-fluorophenyl)-1-(4-phenyl-4-{[3,5-bis(trifluoromethyl)phenyl]-prop-1-enyl}cyclohexyl)piperidine 
• 374823-23-1 (E)-4-phenyl-4-{3-[3,5-bis(trifluoromethyl)phenyl]prop-1-enyl}cyclohexanone 
• 374819-33-7 (E)-8-Phenyl-8-{3-[3,5-bis(trifluoromethyl)phenyl]prop-1-enyl}-1,4-dioxaspiro[4.5]decane 

Relevant academic research and scientific papers

Cyclohexyl derivatives and their use as therapeutic agents

The present invention relates compounds of the formula (I): wherein ring A is a phenyl or pyridyl ring; X represents a linker selected from the group consisting of: (a), (b), (c), (d), (e), (f), (g), (h), (i), (j), (k), (l) and R1, R2, R3, R4, R5, R6, R7, R13, R14, R15, R16, R?17, R18, R19, R21a and R21b are as defined herein. The compounds are of particular use in the treatment or prevention of depression, anxiety, pain, inflammation, migraine, emesis or postherpetic neuralgia.

4,4-Disubstituted cyclohexylamine NK(1) receptor antagonists I.

A series of novel 4,4-disubstituted cyclohexylamine based NK(1) antagonists is described. The effect of changes to the C(1)-C(4) relative stereochemistry on the cyclohexane ring and replacements for the flexible linker are discussed, leading to the identification of compounds with high affinity and good in vivo duration of action.